6 ms·
That's a good article with a good point. As a caregiver impatiently waiting for Daraxonrasib, I can at least acknowledge that the institutional machinery is goi
by dmbrThnYou 3mo ago
That's a good article with a good point. As a caregiver impatiently waiting for Daraxonrasib, I can at least acknowledge that the institutional machinery is going as fast as it can. I've litterally witnessed a trial patient in the first cohort of a drug (that went no further) be rushed from infusion to the hospital; the trial process cannot be sped up from its current state without endangering lives.
- yelling_cat 3mo ago> As a caregiver impatiently waiting for Daraxonrasib Same here. Are you and your care recipient familiar with the Optune Pax device that the FDA approved in February? https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer https://www.fda.gov/news-events/press-announcements/fda-appr... My father's been using it since April. It's a little cumbersome and only improves overall survival rates by about two months over chemo alone, but we're hoping that it helps him remain relatively healthy until Daraxonrasib becomes available.
- dmbrThnYou 3mo agoThanks for that. I wasn't aware. She doesn't repond well to that regimen, so it doesn't apply to us. We should be alright. We're on track for the expanded access program. Also, it's a long story, but she was taken off an Irinotecan-containing regimen prematurely about a year ago. In hindsight, she was clearly reaponding very well to that particular drug, so we've got that in our toolkit.